Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome (NCT03383575)

🔬

Loading study...

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome (NCT03383575) | TrialReferrals